<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="rapid-communication" dtd-version="2.3">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">molbank</journal-id>
      <journal-title>Molbank</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Molbank</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Molbank</abbrev-journal-title>
      <issn pub-type="epub">1422-8599</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/M746</article-id>
      <article-id pub-id-type="publisher-id">molbank-2011-M746</article-id>
      <article-categories>
        <subj-group>
          <subject>Short Note</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>(<italic>E</italic>)-Ethyl 3-(Dimethylamino)-2-(7,9-diphenyl-7<italic>H</italic>-pyrazolo[4,3-<italic>e</italic>][1,2,4]triazolo[1,5-<italic>c</italic>]pyrimidin-2-yl)acrylate</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Gomha</surname>
            <given-names>Sobhi M.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Farghaly</surname>
            <given-names>Thoraya A.</given-names>
          </name>
          <xref rid="c1-molbank-2011-M746" ref-type="corresp">*</xref>
        </contrib>
      </contrib-group>
      <aff id="af1-molbank-2011-M746">Department of Chemistry, Faculty of Science, University of Cairo, Giza, 12613, Egypt</aff>
      <author-notes>
        <corresp id="c1-molbank-2011-M746"><label>*</label>Author to whom correspondence should be addressed; E-Mail: <email>thoraya-f@hotmail.com</email>.</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>20</day>
        <month>12</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>12</month>
        <year>2011</year>
      </pub-date>
      <volume>2011</volume>
      <issue>4</issue>
      <elocation-id>M746</elocation-id>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>11</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>12</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2011 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <license>
          <p>This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).</p>
        </license>
      </permissions>
      <abstract>
        <p>Novel (<italic>E</italic>)-ethyl 3-(dimethylamino)-2-(7,9-diphenyl-7<italic>H</italic>-pyrazolo[4,3-<italic>e</italic>][1,2,4]triazolo[1,5-<italic>c</italic>]pyrimidin-2-yl)acrylate (<bold>3A</bold>), was prepared <italic>via</italic> condensation of ethyl (1,3-diphenyl-1<italic>H</italic>-pyrazolo[4,3-<italic>e</italic>][1,2,4]triazolo[1,5-<italic>c</italic>]pyrimidin-5-yl)acetate (<bold>1</bold>) and dimethylformamide-dimethylacetal under reflux. The structure of the synthesized compound was assigned on the basis of elemental analysis, IR, <sup>1</sup>H NMR and mass spectral data.</p>
      </abstract>
      <kwd-group>
        <kwd>pyrazolo-triazolo-pyrimidine</kwd>
        <kwd>enaminone</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Enaminones are poly-dentate reagents that have been utilized extensively in this decade as building blocks in organic synthesis [<xref ref-type="bibr" rid="B1-molbank-2011-M746">1</xref>,<xref ref-type="bibr" rid="B2-molbank-2011-M746">2</xref>,<xref ref-type="bibr" rid="B3-molbank-2011-M746">3</xref>,<xref ref-type="bibr" rid="B4-molbank-2011-M746">4</xref>,<xref ref-type="bibr" rid="B5-molbank-2011-M746">5</xref>]. Many reports indicated that the presence of a basic side chain like the <italic>N</italic>,<italic>N</italic>-dialkylaminoalkyl group enhances the drugs&#x2019; DNA affinity [<xref ref-type="bibr" rid="B6-molbank-2011-M746">6</xref>] and their anticancer activity, e.g., against the human breast cancer cell line, MCF-7 [<xref ref-type="bibr" rid="B7-molbank-2011-M746">7</xref>]. In addition, pyrazolo[4,3-<italic>e</italic>][1,2,4]triazolo[1,5-<italic>c</italic>]pyrimidines have been used as potent and selective adenosine A<sub>2A</sub> receptor antagonists [<xref ref-type="bibr" rid="B8-molbank-2011-M746">8</xref>,<xref ref-type="bibr" rid="B9-molbank-2011-M746">9</xref>,<xref ref-type="bibr" rid="B10-molbank-2011-M746">10</xref>,<xref ref-type="bibr" rid="B11-molbank-2011-M746">11</xref>,<xref ref-type="bibr" rid="B12-molbank-2011-M746">12</xref>,<xref ref-type="bibr" rid="B13-molbank-2011-M746">13</xref>,<xref ref-type="bibr" rid="B14-molbank-2011-M746">14</xref>,<xref ref-type="bibr" rid="B15-molbank-2011-M746">15</xref>]. This finding prompted us to condense ethyl (1,3-diphenyl-1<italic>H</italic>-pyrazolo[4,3-<italic>e</italic>][1,2,4]triazolo[1,5-<italic>c</italic>]pyri&#xAD;midin-5-yl)acetate (<bold>1</bold>) [<xref ref-type="bibr" rid="B16-molbank-2011-M746">16</xref>] with dimethylformamide-dimethylacetal (DMF-DMA) to obtain the title compound <bold>3A</bold> (<xref ref-type="scheme" rid="molbank-2011-M746-sch001">Scheme 1</xref>). Elemental analyses and spectral data were in complete accordance with the assigned structure <bold>3</bold>. For example, the <sup>1</sup>H NMR spectrum of compound <bold>3</bold> revealed two singlet signals at <italic>&#x3B4;</italic> 3.30 and 7.77 ppm characteristic for <italic>N,N</italic>-dimethylamino and the exocyclic C=CH protons, respectively [<xref ref-type="bibr" rid="B1-molbank-2011-M746">1</xref>]. The value of the exocyclic C=CH proton signal at <italic>&#x3B4;</italic> 7.77 ppm correlated with the <italic>E</italic>-isomer (<bold>3A</bold>), while the <italic>Z</italic>-isomer <bold>3B</bold> of an analogous structure was reported to appear at <italic>&#x3B4;</italic> 6.9 ppm [<xref ref-type="bibr" rid="B17-molbank-2011-M746">17</xref>]. Thus, we have successfully synthesized a new enaminone in good yield which can be used as a building blocks for heterocyclic ring systems in organic synthesis.</p>
      <p><bold>Synthesis of (<italic>E</italic>)-ethyl 3-(dimethylamino)-2-(7,9-diphenyl-7<italic>H</italic>-pyrazolo[4,3-<italic>e</italic>][1,2,4]triazolo[1,5-<italic>c</italic>]pyrimidin-2-yl)acrylate (3)</bold></p>
      <p>A mixture of <bold>1</bold> (4.3 g, 10 mmol) and dimethylformamide-dimethylacetal (10 mL) was refluxed for 20 min. After cooling, the precipitate was collected by filtration, washed with methanol and crystallized from dioxane. </p>
      <p>Yield: 92%; pale yellow crystals; m.p. 240 &#xB0;C. </p>
      <p>GC-MS <italic>m/z</italic> (%): 454 (M<sup>+</sup>+ 1, 4), 453 (M<sup>+</sup>, 13), 380 (11), 336 (12), 167 (23),77 (100), 51 (48).</p>
      <p>IR (KBr) <italic>v</italic><sub>max</sub> cm<sup>&#x2212;1</sup>: 1624 (C=O). </p>
      <p><sup>1</sup>H NMR (Bruker, 300 MHz, CDCl<sub>3</sub>): <italic>&#x3B4;</italic> (ppm) = 1.13 (t, <italic>J</italic> = 7.0 Hz, 3H, CH<sub>3</sub>), 3.30 (s, 6H, 2 CH<sub>3</sub>), 4.07 (q, <italic>J</italic> = 7.0 Hz, 2H, CH<sub>2</sub>), 7.47-8.7 (m, 10H, Ar-H), 7.77 (s, 1H, =CH), 9.68 (s, 1H, pyrimidine-H). </p>
      <p>Anal. Calcd. for C<sub>25</sub>H<sub>23</sub>N<sub>7</sub>O<sub>2</sub> (453.19): C, 66.21; H, 5.11; N, 21.62. Found: C, 66.11; H, 5.01; N, 21.39%. </p>
  </body>
  <back>
    <app-group>
    <app id="app1-molbank-2011-M746">
        <title>Supplementary materials</title>
        <supplementary-material id="molbank-2011-M746-s001" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2011-M746-s001-mod.mol">
   <label>Supplementary File 1</label>
</supplementary-material>
        <supplementary-material id="molbank-2011-M746-s002" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2011-M746-s001.mol">
   <label>Supplementary File 2</label>
</supplementary-material>
    </app>
</app-group>
 <ref-list>
      <title>References</title>
      <ref id="B1-molbank-2011-M746">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farghaly</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Abdel Hafez</surname>
              <given-names>N.A.</given-names>
            </name>
            <name>
              <surname>Ragab</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Awad</surname>
              <given-names>H.M.</given-names>
            </name>
            <name>
              <surname>Abdalla</surname>
              <given-names>M.M.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis, anti-HCV, antioxidant, and peroxynitrite inhibitory activity of fused benzosuberone derivatives</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2010</year>
          <volume>45</volume>
          <fpage>492</fpage>
          <lpage>500</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2009.10.033</pub-id>
          <pub-id pub-id-type="pmid">19913334</pub-id>
        </citation>
      </ref>
      <ref id="B2-molbank-2011-M746">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shawali</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Farghaly</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Al-Dahshoury</surname>
              <given-names>A.R.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis, reactions and antitumor activity of new &#x3B2;-aminovinyl 3- pyrazolyl ketones</article-title>
          <source>ARKIVOC</source>
          <year>2009</year>
		  <volume>xiv</volume>
          <fpage>88</fpage>
          <lpage>89</lpage>
        </citation>
      </ref>
      <ref id="B3-molbank-2011-M746">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farghaly</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Abdalla</surname>
              <given-names>M.M.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones</article-title>
          <source>Bioorg. Med. Chem.</source>
          <year>2009</year>
          <volume>17</volume>
          <fpage>8012</fpage>
          <lpage>8019</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmc.2009.10.012</pub-id>
          <pub-id pub-id-type="pmid">19864149</pub-id>
        </citation>
      </ref>
      <ref id="B4-molbank-2011-M746">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farghaly</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Riyadh</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>Microwave assisted synthesis of annelated benzosuberone as new penta-heterocyclic ring systems</article-title>
          <source>ARKIVOC</source>
          <year>2009</year>
          <volume>x</volume>
          <fpage>54</fpage>
          <lpage>63</lpage>
        </citation>
      </ref>
      <ref id="B5-molbank-2011-M746">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Riyadh</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Farghaly</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Abdallah</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Abdalla</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Abd El-Aziz</surname>
              <given-names>M.R.</given-names>
            </name>
          </person-group>
          <article-title>New pyrazoles incorporating pyrazolylpyrazole moiety: Synthesis, anti-HCV and antitumor activity</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2010</year>
          <volume>45</volume>
          <fpage>1042</fpage>
          <lpage>1050</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2009.11.050</pub-id>
          <pub-id pub-id-type="pmid">20022411</pub-id>
        </citation>
      </ref>
      <ref id="B6-molbank-2011-M746">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ducrocq</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Wendling</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Tourbez-Perrin</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rivalle</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Tambourin</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Pochon</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Bisagni</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Chermann</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>Structure-activity relationship in a series of newly synthesized 1-amino-substituted ellipticine derivatives</article-title>
          <source>J. Med. Chem.</source>
          <year>1980</year>
          <volume>23</volume>
          <fpage>1212</fpage>
          <pub-id pub-id-type="doi">10.1021/jm00185a012</pub-id>
          <pub-id pub-id-type="pmid">7452670</pub-id>
        </citation>
      </ref>
      <ref id="B7-molbank-2011-M746">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahmed</surname>
              <given-names>M.S.M.</given-names>
            </name>
            <name>
              <surname>Farghaly</surname>
              <given-names>T.A.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and reactions of 3-hydrazino-2,7,8,9-tetrahydro-1<italic>H</italic>-benzo[6&#x2032;,7&#x2032;]cyclohepta[1&#x2032;,2&#x2032;:4,5]pyrido[2,3-<italic>d</italic>]pyrimidin-1-one</article-title>
          <source>ARKIVOC</source>
          <year>2009</year>
		  <volume>xiii</volume>
          <fpage>31</fpage>
          <lpage>41</lpage>
        </citation>
      </ref>
      <ref id="B8-molbank-2011-M746">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ongini</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Monopoli</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cacciari</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Baraldi</surname>
              <given-names>P.G.</given-names>
            </name>
          </person-group>
          <article-title>Selective adenosine A<sub>2A</sub> receptor antagonists</article-title>
          <source>Il Farmaco</source>
          <year>2001</year>
          <volume>56</volume>
          <fpage>87</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="doi">10.1016/S0014-827X(01)01024-2</pub-id>
        </citation>
      </ref>
      <ref id="B9-molbank-2011-M746">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kishore</surname>
              <given-names>D.P.</given-names>
            </name>
            <name>
              <surname>Balakumar</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>A.R.</given-names>
            </name>
            <name>
              <surname>Roy</surname>
              <given-names>P.P.</given-names>
            </name>
            <name>
              <surname>Roy</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>QSAR of adenosine receptor antagonists: Exploring physicochemical requirements for binding of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives with human adenosine A3 receptor subtype</article-title>
          <source>Bioorg. Med. Chem. Let.</source>
          <year>2011</year>
          <volume>21</volume>
          <fpage>818</fpage>
          <lpage>823</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmcl.2010.11.094</pub-id>
          <pub-id pub-id-type="pmid">21163647</pub-id>
        </citation>
      </ref>
      <ref id="B10-molbank-2011-M746">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baraldi</surname>
              <given-names>P.G.</given-names>
            </name>
            <name>
              <surname>Manfredini</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Simoni</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Zappaterra</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Zocchi</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Dionisotti</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ongini</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of new pyrazolo[4,3-<italic>e</italic>]1,2,4-triazolo[1,5-<italic>c</italic>]pyrimidine and 1,2,3-triazolo[4,5-<italic>e</italic>]1,2,4-triazolo[1,5-<italic>c</italic>]pyrimidine displaying potent and selective activity as A<sub>2a</sub> adenosine receptor antagonists</article-title>
          <source>Bioorg. Med. Chem. Lett.</source>
          <year>1994</year>
          <volume>4</volume>
          <fpage>2539</fpage>
          <lpage>2544</lpage>
          <pub-id pub-id-type="doi">10.1016/S0960-894X(01)80279-1</pub-id>
        </citation>
      </ref>
      <ref id="B11-molbank-2011-M746">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumar</surname>
              <given-names>T.S.</given-names>
            </name>
            <name>
              <surname>Mishra</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Deflorian</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Yoo</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Phan</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kecsk&#xE9;s</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Szabo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Shinkre</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>Z.-G.</given-names>
            </name>
            <name>
              <surname>Trenkle</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Jacobson</surname>
              <given-names>K.A.</given-names>
            </name>
          </person-group>
          <article-title>Molecular probes for the A<sub>2A</sub> adenosine receptor based on a pyrazolo[4,3-<italic>e</italic>][1,2,4]triazolo[1,5-<italic>c</italic>]pyrimidin-5-amine scaffold</article-title>
          <source>Bioorg. Med. Chem. Lett.</source>
          <year>2011</year>
          <volume>21</volume>
          <fpage>2740</fpage>
          <lpage>2745</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmcl.2010.11.082</pub-id>
          <pub-id pub-id-type="pmid">21185184</pub-id>
        </citation>
      </ref>
      <ref id="B12-molbank-2011-M746">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harris</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Neustadt</surname>
              <given-names>B.R.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Lachowicz</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Cohen-Williams</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Varty</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Hao</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Stamford</surname>
              <given-names>A.W.</given-names>
            </name>
          </person-group>
          <article-title>Potent and selective adenosine A<sub>2A</sub> receptor antagonists: [1,2,4]Triazolo[4,3-c]pyrimidin-3-ones</article-title>
          <source>Bioorg. Med. Chem. Lett.</source>
          <year>2011</year>
          <volume>21</volume>
          <fpage>2497</fpage>
          <lpage>2501</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmcl.2011.02.045</pub-id>
          <pub-id pub-id-type="pmid">21398125</pub-id>
        </citation>
      </ref>
      <ref id="B13-molbank-2011-M746">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baraldi</surname>
              <given-names>P.G.</given-names>
            </name>
            <name>
              <surname>Bovero</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Fruttarolo</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Romagnoli</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Tabrizi</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Preti</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Varani</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Borea</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Moorman</surname>
              <given-names>A.R.</given-names>
            </name>
          </person-group>
          <article-title>New strategies for the synthesis of A<sub>3</sub> adenosine receptor antagonists</article-title>
          <source>Bioorg. Med. Chem.</source>
          <year>2003</year>
          <volume>11</volume>
          <fpage>4161</fpage>
          <lpage>4169</lpage>
          <pub-id pub-id-type="doi">10.1016/S0968-0896(03)00484-X</pub-id>
        </citation>
      </ref>
      <ref id="B14-molbank-2011-M746">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Michielan</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Bolcato</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Federico</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Cacciari</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Bacilieri</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Klotz</surname>
              <given-names>K.-N.</given-names>
            </name>
            <name>
              <surname>Kachler</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Pastorin</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Cardin</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Sperduti</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Spalluto</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Moro</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A<sub>2A</sub> and A<sub>3</sub> receptor pyrazolo-triazolo-pyrimidine antagonists binding sites</article-title>
          <source>Bioorg. Med. Chem.</source>
          <year>2009</year>
          <volume>17</volume>
          <fpage>5259</fpage>
          <lpage>5274</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmc.2009.05.038</pub-id>
          <pub-id pub-id-type="pmid">19501513</pub-id>
        </citation>
      </ref>
      <ref id="B15-molbank-2011-M746">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paeshuyse</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Letellier</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Froeyen</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Dutartre</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Vrancken</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Canard</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>De Clercq</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Gueiffier</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Teulade</surname>
              <given-names>J.-C.</given-names>
            </name>
            <name>
              <surname>Herdewijn</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Puerstinger</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Koenen</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Kerkhofs</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Baraldi</surname>
              <given-names>P.G.</given-names>
            </name>
            <name>
              <surname>Neyts</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>A pyrazolotriazolopyrimidinamine inhibitor of bovine viral diarrhea virus replication that targets the viral RNA-dependent RNA polymerase</article-title>
          <source>Antivir. Res.</source>
          <year>2009</year>
          <volume>82</volume>
          <fpage>141</fpage>
          <lpage>147</lpage>
          <pub-id pub-id-type="doi">10.1016/j.antiviral.2009.02.192</pub-id>
          <pub-id pub-id-type="pmid">19428605</pub-id>
        </citation>
      </ref>
      <ref id="B16-molbank-2011-M746">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farghaly</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Gomha</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of ethyl (1,3-diphenyl-1<italic>H</italic>-pyrazolo[4,3-<italic>e</italic>][1,2,4] triazolo&#xAD;[1,5-<italic>c</italic>]pyrimidin-5-yl)acetate</article-title>
          <source>Molbank</source>
          <year>2011</year>
          <volume>2011</volume>
          <fpage>M743</fpage>
          <pub-id pub-id-type="doi">10.3390/M743</pub-id>
        </citation>
      </ref>
      <ref id="B17-molbank-2011-M746">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bennett</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Donnelly</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Meaney</surname>
              <given-names>D.C.</given-names>
            </name>
            <name>
              <surname>Boyle</surname>
              <given-names>P.O.</given-names>
            </name>
          </person-group>
          <article-title>Stereochemistry of cyclopropyl ketones from the reaction of dimethylsulphoxonium methylide with 3-benzylidenechroman-4-ones</article-title>
          <source>J. Chem. Soc. Perkin Trans. 1</source>
          <year>1972</year>
          <fpage>1554</fpage>
          <pub-id pub-id-type="doi">10.1039/p19720001554</pub-id>
        </citation>
      </ref>
    </ref-list>
    <sec sec-type="display-objects">
      <title>Scheme</title>
      <fig id="molbank-2011-M746-sch001" position="float">
        <object-id pub-id-type="pii">molbank-2011-M746-sch001_Scheme 1</object-id>
        <label>Scheme 1</label>
        <caption>
          <p>Synthesis of the title compound (<bold>3A</bold>).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2011-M746-sch001.tif"/>
      </fig>
    </sec>
  </back>
</article>
